liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Resveratrol analogue 4,4 -dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis
University of Pavia, Italy.
University of Pavia, Italy.
University of Pavia, Italy.
University of Pavia, Italy.
Show others and affiliations
2016 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 6, no 19973Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

We investigated the preventive effects of resveratrol analogue 4,4-dihydroxy-trans-stilbene (DHS) on cancer invasion and metastasis. Two different in vivo approaches of mouse and zebrafish lung cancer invasion models were employed in our study. The in vitro results showed that DHS displays potent inhibition on anchorage-dependent or -independent cell growth of LLC cells, leading to impairment of the cell cycle progression with reduction of cell numbers arresting at the G1 phase, an evident accumulation of pre-G1 events correlated with apoptotic behaviour. In addition, DHS induces a marked inhibition of LLC cell migration and matrigel invasion. In a murine lung cancer model, tumour volume, cell proliferation, and tumour angiogenesis were significantly inhibited by DHS. Importantly, liver metastatic lesions were significantly reduced in DHS-treated mice. Similarly, DHS significantly inhibits lung cancer cell dissemination, invasion and metastasis in a zebrafish tumour model. These findings demonstrate that DHS could potentially be developed as a novel therapeutic agent for treatment of cancer and metastasis.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2016. Vol. 6, no 19973
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-125145DOI: 10.1038/srep19973ISI: 000368988600001PubMedID: 26829331OAI: oai:DiVA.org:liu-125145DiVA: diva2:903426
Note

Funding Agencies|Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale [PRIN 2008PK2WCW_002]

Available from: 2016-02-15 Created: 2016-02-15 Last updated: 2017-11-30

Open Access in DiVA

fulltext(2122 kB)63 downloads
File information
File name FULLTEXT01.pdfFile size 2122 kBChecksum SHA-512
dfaa07537a2b2c24b62d812bb4141abcb5e0b9719e39a45449057f986910415e324bc8bc061c85cf6ead1d36dbe98a08fabe77dc12fd160625b189597ff7d62b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Jensen, Lasse

Search in DiVA

By author/editor
Jensen, Lasse
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Clinical Pharmacology
In the same journal
Scientific Reports
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 63 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 445 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf